A home NAD+ injection and an IV infusion both use a needle, but they are different routes and care arrangements. An IV enters a vein; a subcutaneous injection is placed under the skin and is not the same as immediate intravenous delivery.
The choice cannot be settled by saying one is stronger or comparing a vial with an infusion bag. The relevant questions concern the proposed preparation, evidence, clinical supervision, practical responsibilities, and complete cost.
IV and subcutaneous NAD are different interventions. Compare evidence, supervision, responsibilities, and complete cost; an IV study does not supply a home-injection protocol.
The route changes the exposure question
An IV introduces the preparation into the circulation, while subcutaneous administration involves absorption from the injection site. Those differences can affect the timing of exposure. They do not by themselves establish which approach produces a better clinical outcome.
Ask a provider to distinguish pharmacology from a demonstrated benefit. “Bypasses digestion” applies to several non-oral routes and does not prove that each has the same effect or the same evidence.
The best-known IV pilot is not a home-shot trial
The 2019 NAD pilot examined metabolism during a six-hour IV intervention. Its 750 mg study amount does not provide a schedule for a home vial. A later retrospective tolerability study also concerns a specific IV setting rather than proving home-injection effectiveness.
A clinic or online service should identify evidence matching its own route and the outcome being discussed. Neither a route description nor a small pilot establishes a longevity benefit.
Supervision and home responsibilities differ
In-person infusion care allows direct observation during the appointment, but the quality and appropriateness of that care still need to be assessed. Ask who evaluates you, who administers treatment, and how symptoms are handled.
A home prescription places storage, label reading, and other practical responsibilities with the patient, supported by the clinical and pharmacy teams. Our home-injection guide explains the questions to resolve before receiving a shipment.
Compare the full visit or supply period
An infusion quote may cover one appointment, while an online price may cover a vial or recurring supply. Ask what includes evaluation, administration, supplies, travel, and follow-up. A per-shot comparison is incomplete when providers define the amount differently.
Use the cost guide and your state guide to account for the actual appointment location. A cheaper product price may still involve a care arrangement that does not fit your circumstances.
What should guide the discussion
Start with the health concern and the evidence for addressing it, then ask whether the proposed route is appropriate. Identify the pharmacy and obtain the product-specific label and clinical instructions. Compounded NAD preparations are not FDA-approved.
Do not translate an IV total into a home injection amount or repurpose an oral product for injection. If the real priority is avoiding needles, nasal versus injection care addresses another route with its own evidence limits.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Grant et al. (2019): NAD+ infusion metabolome pilot Small human IV study; metabolic observations do not prove longevity or everyday benefits.
- Reyna et al. (2026): retrospective IV tolerability pilot Route-specific retrospective tolerability evidence; not proof of effectiveness for home injections.
- FDA: ingredients suitable for sterile compounding Safety notice describing reported reactions and ingredient-quality concerns.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.